{
  "id": "6404199d201352f04a000019",
  "type": "yesno",
  "question": "Is ocrelizumab effective for primary progressive multiple sclerosis?",
  "ideal_answer": "Yes, ocrelizumab is effective and approved for primary progressive multiple sclerosis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35583174",
    "http://www.ncbi.nlm.nih.gov/pubmed/35590041",
    "http://www.ncbi.nlm.nih.gov/pubmed/35192158"
  ],
  "snippets": [
    {
      "text": "Ocrelizumab (Ocrevus\u00ae) is an intravenously administered, humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35192158",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "When using the anti-CD20 monoclonal antibodies ocrelizumab and ofatumumab in the treatment of MS, it is not necessary to test for NAbs as these occur very infrequently. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35590041",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ocrelizumab for multiple sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583174",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Ocrelizumab is a humanised anti-CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in adults with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583174",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}